{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:01:25Z","timestamp":1777669285980,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"publisher","award":["014 D09 301 003-702"],"award-info":[{"award-number":["014 D09 301 003-702"]}],"id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jconrel.2017.06.032","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T17:01:20Z","timestamp":1499101280000},"page":"187-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles"],"prefix":"10.1016","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4292-9761","authenticated-orcid":false,"given":"Emine","family":"Sekerdag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevda","family":"L\u00fcle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Bozda\u011f Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7617-8433","authenticated-orcid":false,"given":"Naile","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Kaffashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkay","family":"I\u015f\u0131kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bur\u04abin","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kader Karl\u0131","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Figen","family":"S\u00f6ylemezo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"G\u00fcrsoy-\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melike","family":"Mut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2017.06.032_bb0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11910-011-0189-8","article-title":"Current state of our knowledge on brain tumor epidemiology","volume":"11","author":"Ostrom","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0010","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisions of radiotheraphy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2017.06.032_bb0015","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1021\/mp100298r","article-title":"Targeted imaging and therapy of brain cancer using theranostic nanoparticles","volume":"7","author":"Bhojani","year":"2010","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2017.06.032_bb0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.nano.2011.02.008","article-title":"Could nanoparticle systems have a role in the treatment of cerebral gliomas?","volume":"7","author":"Caruso","year":"2011","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2017.06.032_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/157489211793979990","article-title":"Nanotechnology advances in brain tumors: the state of the art","volume":"6","author":"Invernici","year":"2011","journal-title":"Recent. Pat. Anticancer Drug Discov."},{"issue":"4","key":"10.1016\/j.jconrel.2017.06.032_bb0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/03639045.2011.608191","article-title":"Nanostructure-based drug delivery systems for brain targeting","volume":"38","author":"Haque","year":"2012","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0035","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cancers5031020","article-title":"Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM?","volume":"5","author":"van Woensel","year":"2013","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jconrel.2017.06.032_bb0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/1567201812666150507120124","article-title":"Nose to brain delivery of midazolam loaded PLGA nanoparticles: in vitro and in vivo investigations","volume":"13","author":"Sharma","year":"2016","journal-title":"Current Drug Deliv."},{"issue":"10","key":"10.1016\/j.jconrel.2017.06.032_bb0045","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/mt.2011.164","article-title":"Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain","volume":"19","author":"Zhuang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2016.02.032","article-title":"Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration","volume":"227","author":"Van Woensel","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2017.06.032_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2017.06.032_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0272-0590(92)90161-A","article-title":"Accumulation of Cd(II) in the CNS depending on the route of administration: intraperitoneal, intratracheal, or intranasal","volume":"19","author":"Evans","year":"1992","journal-title":"Fundam. Appl. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2017.06.032_bb0065","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4615-1899-0_10","article-title":"Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes","volume":"380","author":"Perlman","year":"1995","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.jconrel.2017.06.032_bb0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/713714452","article-title":"Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier","volume":"10","author":"Minn","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0080","doi-asserted-by":"crossref","first-page":"11709","DOI":"10.1158\/0008-5472.CAN-06-1878","article-title":"A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration","volume":"66","author":"Goldberg","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2017.06.032_bb0085","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1535-7163.MCT-06-0193","article-title":"Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis","volume":"5","author":"Blum","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2017.06.032_bb0090","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.999.65.3","article-title":"Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1\u03b1, causing glycolysis shutdown and cell death","volume":"65","author":"Blum","year":"2005","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2017.06.032_bb0095","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1158\/1535-7163.MCT-08-0488","article-title":"Mardor. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats","volume":"7","author":"Goldberg","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.jconrel.2017.06.032_bb0100","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-06-0792","article-title":"The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1","volume":"12","author":"Barkan","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2017.06.032_bb0105","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jchromb.2008.05.028","article-title":"Determination of salirasib (S-trans, trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography\u2013tandem mass spectrometry","volume":"869","author":"Zhao","year":"2008","journal-title":"J. Chromatogr. B"},{"issue":"7","key":"10.1016\/j.jconrel.2017.06.032_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","article-title":"Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies","volume":"15","author":"Badar","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.jconrel.2017.06.032_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00280-009-1027-4","article-title":"Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors","volume":"65","author":"Tsimberidou","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl. 9","key":"10.1016\/j.jconrel.2017.06.032_bb0120","article-title":"128OPhase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in Japanese patients with advanced solid tumors","volume":"26","author":"Shimizu","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2017.06.032_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1021\/jm801165r","article-title":"New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models","volume":"52","author":"Goldberg","year":"2009","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2017.06.032_bb0130","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1021\/mp500181x","article-title":"PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel","volume":"11","author":"Zhang","year":"2014","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2017.06.032_bb0135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1208\/s12248-014-9595-6","article-title":"Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system","volume":"16","author":"Chen","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.actbio.2016.07.014","article-title":"A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel","volume":"43","author":"Sun","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0145","unstructured":"S Pehlivan, I Vural, A Kaffasi, S L\u00fcle, H Ko\u015fucu, M Mut A\u015fkun, T Demir, C Saris\u00f6zen, E Bu\u011fdayci, F S\u00f6ylemezoglu. Nanoparticle formulation containing farnesylthiosalicylic acid (salirasib). Patent application (WO2015167408); 2015."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0150","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0142-9612(00)00103-4","article-title":"Biodegradable poly(D,L-lactic acid)-poly(ethylene glycol)-monomethyl ether diblock copolymers: structures and surface properties relevant to their use as biomaterials","volume":"21","author":"Lucke","year":"2000","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2017.06.032_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/0929867043456142","article-title":"Modeling of cationic lipid-DNA complexes","volume":"11","author":"May","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2017.06.032_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02652049809006831","article-title":"Polymer-coated long-circulating microparticulate pharmaceuticals","volume":"15","author":"Torchilin","year":"1998","journal-title":"J. Microencapsul."},{"issue":"26","key":"10.1016\/j.jconrel.2017.06.032_bb0165","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.biomaterials.2011.05.024","article-title":"Yang. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles","volume":"32","author":"AJ Cole","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.06.032_bb0170","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1124\/jpet.102.039669","article-title":"Poly(ethylene glycol)- coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting","volume":"303","author":"Brigger","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2017.06.032_bb0175","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0180","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Dmitri","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2017.06.032_bb0185","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1023\/A:1016486910719","article-title":"Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery","volume":"19","author":"Kaul","year":"2002","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2017.06.032_bb0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijpharm.2011.09.039","article-title":"Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting","volume":"421","author":"Agarwal","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"35","key":"10.1016\/j.jconrel.2017.06.032_bb0195","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1016\/j.biomaterials.2009.08.040","article-title":"Yang. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking","volume":"30","author":"Chertok","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.06.032_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10611860600721051","article-title":"The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats","volume":"14","author":"QZ Zhang","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0205","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11095-009-0041-x","article-title":"Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy","volume":"27","author":"Jain","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0210","doi-asserted-by":"crossref","first-page":"9726","DOI":"10.1002\/anie.200803526","article-title":"Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that \u201cslip\u201d through the human mucus barrier","volume":"47","author":"Wang","year":"2008","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"6","key":"10.1016\/j.jconrel.2017.06.032_bb0215","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"Zundelevich","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2017.06.032_bb0220","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.fct.2012.01.038","article-title":"Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats","volume":"50","author":"Jaggi","year":"2012","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.jconrel.2017.06.032_bb0225","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jhep.2004.04.010","article-title":"Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid","volume":"41","author":"Reif","year":"2004","journal-title":"J. Hepatol."},{"issue":"Suppl. 18","key":"10.1016\/j.jconrel.2017.06.032_bb0230","article-title":"Abstract 1561: Ras\/Raf\/p38 MAPK\/ERK pathway is activated in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats","volume":"118","author":"Kishi","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jconrel.2017.06.032_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.nic.2010.04.008","article-title":"Jackson. Imaging of brain tumors: perfusion\/permeability","volume":"20","author":"Thompson","year":"2010","journal-title":"Neuroimaging Clin. N. Am."},{"issue":"4","key":"10.1016\/j.jconrel.2017.06.032_bb0240","first-page":"378","article-title":"Tamvakopoulos. Comparison of the effects of perfusion in determining brain penetration (brain-to-plasma ratios) of small molecules in rats","volume":"54","author":"Fenyk-Melody","year":"2004","journal-title":"Comp. Med."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0245","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/la103576a","article-title":"Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method","volume":"26","author":"RH Fang","year":"2010","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2017.06.032_bb0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.colsurfb.2007.08.011","article-title":"Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification","volume":"61","author":"Gasparini","year":"2008","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"6","key":"10.1016\/j.jconrel.2017.06.032_bb0255","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1227\/01.NEU.0000245607.99946.8F","article-title":"Treatment of malignant gliomas with mitoxantrone-loaded poly(lactide-co-glycolide) microspheres","volume":"59","author":"Yemisci","year":"2006","journal-title":"Neurosurgery"},{"issue":"8","key":"10.1016\/j.jconrel.2017.06.032_bb0260","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/neuonc\/noq023","article-title":"Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models","volume":"12","author":"Geletneky","year":"2010","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2017.06.032_bb0265","doi-asserted-by":"crossref","DOI":"10.1111\/jphp.12740","article-title":"Farnesylthiosalicylic acid-loaded lipid\u2013polyethylene glycol\u2013polymer hybrid nanoparticles for treatment of glioblastoma","author":"Kaffashi","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.06.032_bb0270","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0277-5379(82)90200-0","article-title":"Radiation and drug response of the rat glioma RG2","volume":"18","author":"Weizsacker","year":"1982","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2017.06.032_bb0275","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2017.06.032_bb0280","doi-asserted-by":"crossref","first-page":"144","DOI":"10.18632\/oncotarget.420","article-title":"Ras inhibition by FTS attenuates brain tumor growth in mice directly and by enhancing reactivity of cytotoxic lymphocytes","volume":"3","author":"Aizman","year":"2012","journal-title":"Oncotarget"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591730696X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591730696X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:12:29Z","timestamp":1750464749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591730696X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":56,"alternative-id":["S016836591730696X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.06.032","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}